Crescita Therapeutics Inc.
CTX.TO
TSX
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 2.46M | 4.93M | 2.64M | 2.99M | 3.71M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 2.46M | 4.93M | 2.64M | 2.99M | 3.71M |
| Cost of Revenue | 1.25M | 2.79M | 1.19M | 1.35M | 1.92M |
| Gross Profit | 1.22M | 2.14M | 1.44M | 1.63M | 1.79M |
| SG&A Expenses | 1.62M | 1.87M | 1.96M | 2.06M | 1.92M |
| Depreciation & Amortization | 246.00K | 260.70K | 228.80K | 222.20K | 285.60K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.20M | 5.03M | 3.49M | 3.75M | 4.25M |
| Operating Income | -740.00K | -100.70K | -859.30K | -763.00K | -542.20K |
| Income Before Tax | -649.40K | -125.70K | -759.60K | -676.70K | -464.30K |
| Income Tax Expenses | -- | -10.00K | -- | -- | -- |
| Earnings from Continuing Operations | -649.40K | -115.70K | -759.60K | -676.70K | -464.30K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -649.40K | -115.70K | -759.60K | -676.70K | -464.30K |
| EBIT | -740.00K | -100.70K | -859.30K | -763.00K | -542.20K |
| EBITDA | -494.00K | 67.50K | -630.50K | -540.80K | -256.60K |
| EPS Basic | -0.03 | -0.01 | -0.04 | -0.03 | -0.02 |
| Normalized Basic EPS | -0.02 | 0.00 | -0.02 | -0.02 | -0.01 |
| EPS Diluted | -0.03 | -0.01 | -0.04 | -0.04 | -0.02 |
| Normalized Diluted EPS | -0.02 | 0.00 | -0.02 | -0.02 | -0.01 |
| Average Basic Shares Outstanding | 19.03M | 19.12M | 19.27M | 19.44M | 19.59M |
| Average Diluted Shares Outstanding | 19.03M | 19.12M | 19.27M | 19.44M | 19.59M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |